Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology · 01.01.2024 · 160 (1) · 71
DOI: 10.1001/jamadermatol.2023.4846 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.01.2024. Verfasst von Ali Al-Janabi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Ki…. Hauptthemen laut MEDLINE: Biological Products, Eczema, Psoriasis. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Importance Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown.
Objective
To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema. Design, Setting, and Participants This prospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register for adults treated with biologics for plaque psoriasis who were seen at multicenter dermatology clinics in the UK and Ireland. Included participants were registered and had 1 or more follow-up visits between September 2007 and December 2022. Exposures Duration of exposure to tumor necrosis factor (TNF) inhibitors, interleukin (IL) 17 inhibitors, IL-12/23 inhibitors, or IL-23 inhibitors until paradoxical eczema onset, treatment discontinuation, last follow-up, or death. Main Outcomes and Measures Incidence rates of paradoxical eczema, paradoxical eczema risk by biologic class, and the association of demographic and clinical variables with risk of paradoxical eczema were assessed using propensity score–weighted Cox proportional hazards regression models.
Results
Of 56 553 drug exposures considered, 24 997 from 13 699 participants were included. The 24 997 included exposures (median age, 46 years [IQR, 36-55 years]; 57% male) accrued a total exposure time of 81 386 patient-years. A total of 273 exposures (1%) were associated with paradoxical eczema. The adjusted incidence rates were 4.45 per 1000 person-years for IL-17 inhibitors, 3.43 per 1000 person-years for TNF inhibitors, 2.92 per 1000 person-years for IL-12/23 inhibitors, and 2.04 per 1000 person-years for IL-23 inhibitors. Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk of paradoxical eczema (hazard ratio [HR], 0.39; 95% CI, 0.19-0.81), and there was no association of IL-17 inhibitors (HR, 1.03; 95% CI, 0.74-1.42) or IL-12/23 inhibitors (HR, 0.87; 95% CI, 0.66-1.16) with risk of paradoxical eczema. Increasing age (HR, 1.02 per year; 95% CI, 1.01-1.03) and history of AD (HR, 12.40; 95% CI, 6.97-22.06) or hay fever (HR, 3.78; 95% CI, 1.49-9.53) were associated with higher risk of paradoxical eczema. There was a lower risk in males (HR, 0.60; 95% CI, 0.45-0.78). Conclusions and Relevance In this study, in biologic-treated patients with psoriasis, paradoxical eczema risk was lowest in patients receiving IL-23 inhibitors. Increasing age, female sex, and history of AD or hay fever were associated with higher risk of paradoxical eczema. The overall incidence of paradoxical eczema was low. Further study is needed to replicate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
- Dermatology Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.
- Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.
- Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.
- UCB Biopharma, Slough, United Kingdom.
- Institute of Translational and Clinical Medicine, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Department of Dermatology, Medical School, University of Newcastle, Newcastle Hospitals NHS Found…
Förderung
- Medical Research Council
Zitieren
APA
Al-Janabi, A., Alabas, O. A., Yiu, Z. Z. N., Foulkes, A. C., Eyre, S., Khan, A. R., Reynolds, N. J., Smith, C. H., Griffiths, C. E. M., Warren, R. B., & BADBIR Study Group (2024). Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis. JAMA Dermatology, 160(1), 71. https://doi.org/10.1001/jamadermatol.2023.4846
Vancouver
Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, et al. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis. JAMA Dermatology. 2024;160(1):71. doi:10.1001/jamadermatol.2023.4846
BibTeX
@article{AlJanabi2024,
author = {Al-Janabi, Ali and Alabas, Oras A and Yiu, Zenas Z N and Foulkes, Amy C and Eyre, Steve and Khan, Adnan R and Reynolds, Nick J and Smith, Catherine H and Griffiths, Christopher E M and Warren, Richard B and BADBIR Study Group, BADBIR Study Group},
title = {Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {1},
pages = {71},
doi = {10.1001/jamadermatol.2023.4846}
}
EUVIMED